Artiva Biotherapeutics awarded RA Capital Management 16,250 derivative securities on 2026-09-10. The transaction represented 100.0% of RA Capital Management’s resulting derivative securities holding in Artiva, giving investors a precise view of the insider’s post-transaction position and the instrument involved.
Key Highlights
- The transaction was recorded on 10 September 2026.
- The transaction used SEC code A, identifying an award or grant.
- RA Capital Management owned 16,250 derivative securities after the transaction.
Artiva Biotherapeutics, Inc. (NASDAQ: ARTV) recorded an insider award of 16,250 derivative securities to RA Capital Management, L.P. The transaction left RA Capital Management holding 100.0% of its resulting derivative securities position in Artiva.
RA Capital Award Covers Resulting Derivative Holding
RA Capital Management, L.P. is identified as an insider of Artiva Biotherapeutics. The award took place on 10 September 2026 and involved 16,250 derivative securities. After the transaction, RA Capital Management owned 16,250 derivative securities of Artiva Biotherapeutics. That transaction represented about 100.0% of the insider’s resulting derivative securities holding.
FAQs
Q: What did RA Capital Management receive from Artiva Biotherapeutics?
A: RA Capital Management, L.P. identified as an insider of Artiva Biotherapeutics, received an award of 16,250 derivative securities on 10 September 2026. After the transaction, it held 16,250 resulting derivative securities.
Q: What was RA Capital Management’s resulting Artiva holding?
A: RA Capital Management owned 16,250 derivative securities after the Artiva Biotherapeutics transaction. That position represented 100.0% of its resulting derivative securities holding.
Q: When did the Artiva Biotherapeutics insider award occur?
A: The RA Capital Management award occurred on 10 September 2026. The transaction involved Artiva Biotherapeutics derivative securities and was recorded under SEC transaction code A.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.